Name: Karyopharm Therapeutics Inc (KPTI) Fundamental & Financial Data
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is surging following a blowout earnings report that shattered expectations with 93% year-over-year revenue growth and a record-breaking commercial expansion. The community is buzzing over the company's aggressive "sovereign AI" narrative and CEO Alex Karp's pointed attacks on industry competitors, leading to intense debates between bulls celebrating the execution and skeptics questioning the stock's premium valuation.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing increased community interest and speculative discussion as investors weigh the stock's significant cash reserves against its pre-revenue status amidst a volatile semiconductor sector. While some retail traders are expressing frustration over price volatility and lack of frequent corporate updates, others remain bullish, highlighting recent board appointments and strategic partnerships as key signals of an impending commercial ramp-up.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is seeing intense volatility as investors weigh the potential impact of rumored U.S. government restrictions on Chinese data center components against the company's strong reliance on manufacturing within China. The community remains deeply divided, with some traders focused on short-term price swings and heavy institutional interest, while others express concern over long-term margin pressure, supply chain exposure, and the company's historical challenges in achieving profitability.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is currently trending as investors monitor ad market health and speculative interest surrounding upcoming AI AR smartglasses ahead of the next earnings report. The community remains divided, weighing the potential for a growth turnaround against ongoing concerns over leadership control and high litigation risks.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing significant volatility as investors debate whether the company is a deep-value turnaround play following major organizational shifts in China and ongoing competitive pressure. While some traders are expressing frustration over the stock's sluggish movement and recent downgrades, others are actively accumulating shares, viewing the current price as an attractive entry point driven by anticipation of long-term recovery and brand resilience.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is trending as investors aggressively rotate into AI infrastructure and power-intensive data center plays, fueled by bullish hyperscaler capital expenditure outlooks and positive analyst sentiment. The community is actively debating the stock's transition from Bitcoin mining to HPC hosting, with bulls highlighting the potential of its growing development pipeline and behind-the-meter energy solutions.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is at the center of heavy trading volume as investors brace for the company's first earnings report followed by a significant multi-billion dollar share lock-up expiration. The community is sharply divided, with bulls betting on a short squeeze and long-term space infrastructure growth, while bears emphasize the risk of dilution and potential selling pressure from newly unlocked insider shares.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors react to a quarterly report that beat expectations, prompting the company to raise its full-year revenue guidance. The community remains divided, with many expressing frustration over the stock's long-term range-bound performance and management, while others emphasize the appeal of its dividend and the potential for a pipeline turnaround driven by oncology and weight-loss research.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is trending after delivering record-breaking Q2 results that significantly exceeded market expectations, fueled by robust demand for its power and energy segment as data center construction accelerates. Community discourse is heavily focused on whether this sustained growth validates its new role as a core AI-infrastructure play, or if the stock is becoming overvalued as it nears historic highs.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is facing intense scrutiny as it struggles through a five-month losing streak, with investors debating whether the stock represents a deep-value defensive play or a business facing structural decline due to consumer pushback on menu pricing and health concerns. The community is sharply divided, with some betting on a turnaround through dividend stability and technical support levels, while vocal bears argue that the brand's cultural relevance is waning and suggest the stock is prone to further sell-offs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Aug. 3, 2026 NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...

Why Is KPTI Stock Down 69% After-Hours Today?

Equity

Karyopharm said that a key late-stage trial of its drug selinexor in endometrial cancer failed to meet its primary goal. 


Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway PR Newswire NEWTON, Mass., July 30, 2026 Company Plans to Submit sNDA...

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer PR Newswire NEWTON, Mass., July 30, 2026 The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026...

Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of +21.96% and +4.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?

Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., July 1, 2026 NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 PR Newswire NEWTON, Mass., June 3, 2026 NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm...

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 PR Newswire NEWTON...

$KPTI Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.02 up 63.18% YoY
• Reported revenue of $35.07M up 16.83% YoY
• Karyopharm reaffirms full-year 2026 total revenue guidance of $130 million to $150 million, including U.S. XPOVIO net product revenue of $115 million to $130 million for Karyopharm.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.97
Prev Close	$1.92
Open	$1.94
Dividend Yield	0.00%
50-Day Moving Average	$8.71
Beta	0.76
Avg. Volume	1.74M
PE Ratio	-0.13

52-Week High	$10.99
52-Week Low	$1.80
Market Capitalization	$43.51M
EPS (Annual)	-$17.93
Price to Book	-0.17
Revenue Per Employee	$640,644.74

Feed

News

Sentiment

Earnings

Fundamentals

Info